 IRVINE, Calif., July 02, 2021 GLOBE NEWSWIRE -- Eledon Pharmaceuticals, Inc. Eledon NASDAQ: ELDN, a clinical stage biopharmaceutical company focused on developing targeted medicines for persons living with autoimmune disease, requiring an organ or cell-based transplant, or living with amyotrophic lateral sclerosis ALS, today announced the appointment of Jan Hillson, M.D., to the companys Board of Directors. Dr. Hillson currently serves as Senior Vice President of Clinical Development at Alpine Immune Sciences, a clinical stage biopharmaceutical company dedicated to discovering and developing innovative, protein-based immunotherapies targeting the immune synapse to treat cancer and autoimmune and inflammatory diseases. 